1
|
Pacheco-Romero AM, Martín-García Ó, Rey-Sáez R, Boemo T, Blanco I, Vázquez C, Sánchez-López Á. An integrative analysis of potential mechanisms of reduced positive affect in daily life in depression: an ESM study. Cogn Emot 2024:1-18. [PMID: 38329805 DOI: 10.1080/02699931.2024.2314066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2023] [Accepted: 01/30/2024] [Indexed: 02/10/2024]
Abstract
Decreased levels of positive affect (PA) are a hallmark of depression. Current models propose as potential main mechanisms a dysfunctional use of emotion regulation (ER) strategies (i.e. dampening, positive rumination), and a maladaptive activation of pro-hedonic goals. However, the role of these mechanisms in PA in daily life remains understudied. We used a 10-day ESM design to assess how these mechanisms influence each other and contribute to depressive symptomatology-related low momentary PA in 139 individuals. Higher depressive symptoms were associated with lower PA, pro-hedonic goals, more frequent use of positive rumination, and higher use of dampening. Further, experiencing higher levels of PA predicted lower following time point use of dampening in individuals with higher symptoms. Finally, using positive rumination was more beneficial (i.e. predicted higher PA increases one moment later) for individuals with higher symptomatology. Our findings suggest that moment-to-moment changes in PA daily life are affected by, and have an effect on, both pro-hedonic goals and the use of dampening and positive rumination, highlighting specific cognitive-affective mechanisms that should be considered when designing interventions aimed at improving low PA characterising depression symptomatology.
Collapse
Affiliation(s)
- Ana Mar Pacheco-Romero
- Department of Personality, Assessment and Clinical Psychology, Complutense University of Madrid, Madrid, Spain
| | - Óscar Martín-García
- Department of Personality, Assessment and Clinical Psychology, Complutense University of Madrid, Madrid, Spain
| | - Ricardo Rey-Sáez
- Department of Basic Psychology, Autónoma University of Madrid, Madrid, Spain
| | - Teresa Boemo
- Department of Personality, Assessment and Clinical Psychology, Complutense University of Madrid, Madrid, Spain
| | - Iván Blanco
- Department of Personality, Assessment and Clinical Psychology, Complutense University of Madrid, Madrid, Spain
| | - Carmelo Vázquez
- Department of Personality, Assessment and Clinical Psychology, Complutense University of Madrid, Madrid, Spain
| | - Álvaro Sánchez-López
- Department of Personality, Assessment and Clinical Psychology, Complutense University of Madrid, Madrid, Spain
| |
Collapse
|
2
|
Torres-Castro R, Pascual H, Alonso A, Gimeno-Santos E, Palomo M, Barberà JA, Bigorra J, Batlle J, Masip-Bruin X, Blanco I. Use of automatic 6-minute walking test recording system in patients with chronic respiratory diseases. Pulmonology 2023:S2531-0437(23)00166-6. [PMID: 37783641 DOI: 10.1016/j.pulmoe.2023.08.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2023] [Revised: 06/27/2023] [Accepted: 08/31/2023] [Indexed: 10/04/2023] Open
Affiliation(s)
- R Torres-Castro
- Department of Pulmonary Medicine, Hospital Clínic, University of Barcelona, Barcelona, Spain; Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Physical Therapy, Faculty of Medicine, University of Chile, Santiago, Chile
| | - H Pascual
- CRAAX Lab, Universitat Politècnica de Catalunya, Vilanova i la Geltru, Spain
| | - A Alonso
- Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
| | - E Gimeno-Santos
- Department of Pulmonary Medicine, Hospital Clínic, University of Barcelona, Barcelona, Spain; Instituto de Salud Global (ISGlobal), Barcelona, Spain; Biomedical Research Networking Center on Respiratory Diseases (CIBERES); Madrid, Spain
| | - M Palomo
- Department of Pulmonary Medicine, Hospital Clínic, University of Barcelona, Barcelona, Spain
| | - J A Barberà
- Department of Pulmonary Medicine, Hospital Clínic, University of Barcelona, Barcelona, Spain; Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Biomedical Research Networking Center on Respiratory Diseases (CIBERES); Madrid, Spain
| | - J Bigorra
- Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Instituto de Salud Global (ISGlobal), Barcelona, Spain
| | - J Batlle
- Innovation Consultant-Techno & Innovative Solutions, SLU; Vilanova i la Geltrú, Spain
| | - X Masip-Bruin
- CRAAX Lab, Universitat Politècnica de Catalunya, Vilanova i la Geltru, Spain
| | - I Blanco
- Department of Pulmonary Medicine, Hospital Clínic, University of Barcelona, Barcelona, Spain; Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Biomedical Research Networking Center on Respiratory Diseases (CIBERES); Madrid, Spain.
| |
Collapse
|
3
|
Del Pozo R, Blanco I, López-Meseguer M, Escribano-Subías P, Cruz Utrilla A. Effectiveness and persistence with selexipag in pulmonary arterial hypertension in the real-life setting. Eur J Intern Med 2023; 111:140-142. [PMID: 36720652 DOI: 10.1016/j.ejim.2023.01.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/18/2023] [Revised: 01/23/2023] [Accepted: 01/25/2023] [Indexed: 01/31/2023]
Affiliation(s)
- R Del Pozo
- Pneumology Department, Hospital Universitario Juan Ramón Jiménez, Huelva, Spain
| | - I Blanco
- Pneumology Department, Pulmonary Hypertension Unit, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - M López-Meseguer
- Pneumology Depatrment, Hospital Universitario Vall d´Hebrón, Barcelona, Spain
| | - P Escribano-Subías
- Pulmonary Hypertension Unit, Cardiology Department, Hospital Universitario 12 de Octubre, Complutense University, Avenida de Andalucía S/N. 28041 Madrid, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain.
| | - A Cruz Utrilla
- Pulmonary Hypertension Unit, Cardiology Department, Hospital Universitario 12 de Octubre, Complutense University, Avenida de Andalucía S/N. 28041 Madrid, Madrid, Spain
| |
Collapse
|
4
|
Playan Escribano J, Garrido-Lestache E, Luna R, Alvarez Fuente M, Lopez-Meseguer M, Guillen Rodriguez I, Perez Penate GM, Sabate Rotes A, Elias Hernandez T, Lopez Ramon M, Rueda Soriano J, Perin F, Blanco I, Del Cerro Marin MJ, Escribano Subias P. The patient with Down syndrome and pulmonary arterial hypertension associated with congenital heart disease: from childhood to adulthood. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.1850] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Pulmonary arterial hypertension (PAH) is a common complication of congenital heart disease (CHD) that significantly affects its prognosis. Down syndrome is a common comorbidity among patients with PAH associated with CHD. Children born in recent years with CHD have benefited from advances in pediatric cardiac surgery that have modified their evolution compared to adults with the same pathologies. Our objective was to know and compare the characteristics of the adult and pediatric population with DS and PAH associated with CHD.
REHAP and REHIPED are Spanish, voluntary, multicenter registries that include patients with PAH associated with CHD. REHAP started in 2007 and includes patients over 18 years of age. Patients diagnosed with PAH after this time were prospectively included, until 2021. Patients who were followed in the participating centers and diagnosed after January 1998 were retrospectively included in the registry. REHIPED started in 2009 and collects patients between 2 months and 18 years of age. Patients diagnosed with PAH after this time were prospectively included, until 2021. Patients who were followed and diagnosed after January 1998 were retrospectively included. 131 adults and 47 children with DS and PAH associated with CHD were analyzed. Their baseline characteristics, hemodynamics, treatment, and 10-year survival were compared.
Adult patients with DS presented more frequently complete atrioventricular canal defect as underlying heart disease and were mostly in Eisenmenger's situation (84%). In pediatric patients the largest group was post-repair PAH (50%). Functional class was similar in both groups, although adults presented significantly greater hemodynamic severity. Regarding medical treatment, no differences were observed between both groups: there was a very low use of prostanoids both at baseline and at follow-up, and a majority use of oral monotherapy. There were no significant differences in survival.
Corrective surgery in patients with DS has become more frequent over the years: adults are mostly in Eisenmenger's situation, while post-repair PAH is the most numerous group in children. Although adults show greater hemodynamic severity, survival is similar in both groups. Medical treatment, which showed no differences between pediatric and adult age, is very conservative, with most patients on oral monotherapy and rare use of prostanoids.
Funding Acknowledgement
Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Janssen MSD
Collapse
Affiliation(s)
| | | | - R Luna
- University Hospital 12 de Octubre , Madrid , Spain
| | | | | | | | - G M Perez Penate
- University Hospital Dr Negrin , Las Palmas de Gran Canaria , Spain
| | | | - T Elias Hernandez
- Complex Public Hospital Virgen del Rocio Regional, Sevilla , Spain , Spain
| | - M Lopez Ramon
- University Hospital Miguel Servet , Zaragoza , Spain
| | | | - F Perin
- University Hospital Virgen de las Nieves , Granada , Spain
| | - I Blanco
- Hospital Clinic de Barcelona , Barcelona , Spain
| | | | | |
Collapse
|
5
|
Alemany A, Perez-Zsolt D, Raïch-Regué D, Muñoz-Basagoiti J, Ouchi D, Laporte-Villar C, Baro B, Henríquez N, Prat N, Gianinetto MO, Gutiérrez MV, Sánchez-Paniagua MG, Henríquez NL, Vicente JM, Ara J, Rodriguez-Arias MA, Puig J, Blanco I, Lopez CC, Hernández Á, Bordoy AE, Redondo CE, Soler VG, Giménez M, Blanc V, León R, Gispert J, Clotet B, Izquierdo-Useros N, Mitjà O. Cetylpyridinium Chloride Mouthwash to Reduce Shedding of Infectious SARS-CoV-2: A Double-Blind Randomized Clinical Trial. J Dent Res 2022; 101:1450-1456. [PMID: 35727681 DOI: 10.1177/00220345221102310] [Citation(s) in RCA: 22] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
The airborne transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via respiratory fluids and droplets suggests that mouthwashes containing substances with virucidal activity can help reduce viral spread. We conducted a multicenter, double-blind, placebo-controlled, randomized trial to assess the virucidal activity of cetylpyridinium chloride (CPC) mouthwashes. Outpatients who tested positive for SARS-CoV-2 infection with or without symptoms were randomized to perform washes and gargles for 1 min with 15 mL of either colored distilled water or 0.07% CPC (Vitis CPC Protect) mouthwash. The study outcomes were the SARS-CoV-2 log10 viral RNA load and the nucleocapsid protein levels, both in saliva at 1 and 3 h after the intervention. In total, 118 patients were enrolled and randomized (mean [SD], age 46 [14] y). Thirteen of 118 participants (11%) did not complete follow-up or had insufficient sample volume for testing and were excluded from the analysis. The assessment of the viral load showed no significant differences between groups at any of the investigated points. However, the levels of SARS-CoV-2 nucleocapsid protein of lysed viruses were significantly higher in the CPC group compared with the control group at 1 h (adjusted difference 269.3 pg/mL; 95% confidence interval [CI], 97.1-441.5) and at 3 h postintervention (561.1 pg/mL; 95% CI, 380.0-742.2). In nonhospitalized patients with asymptomatic or mild symptomatic SARS-CoV-2 infection, a 0.07% CPC mouthwash, compared to placebo, was associated with a significant increase of nucleocapsid protein levels in saliva, indicating enhanced disruption of viral particles.
Collapse
Affiliation(s)
- A Alemany
- Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.,Hospital Universitari Germans Trias i Pujol, Badalona, Spain.,Facultat de Medicina-Universitat de Barcelona, Barcelona, Spain
| | | | | | | | - D Ouchi
- Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.,Universitat Autònoma de Barcelona, Barcelona, Spain
| | | | - B Baro
- ISGlobal, Hospital Clinic Universitat de Barcelona, Barcelona, Spain
| | - N Henríquez
- Gerència Territorial Metropolitana Nord, Institut Català de la Salut, Barcelona, Spain
| | - N Prat
- Gerència Territorial Metropolitana Nord, Institut Català de la Salut, Barcelona, Spain
| | - M Ochoa Gianinetto
- Gerència Territorial Metropolitana Nord, Institut Català de la Salut, Barcelona, Spain
| | - M Viaplana Gutiérrez
- Gerència Territorial Metropolitana Nord, Institut Català de la Salut, Barcelona, Spain
| | | | - N Larrosa Henríquez
- Gerència Territorial Metropolitana Nord, Institut Català de la Salut, Barcelona, Spain
| | - J Moreno Vicente
- Gerència Territorial Metropolitana Nord, Institut Català de la Salut, Barcelona, Spain
| | - J Ara
- Hospital Universitari Germans Trias i Pujol, Badalona, Spain.,Gerència Territorial Metropolitana Nord, Institut Català de la Salut, Barcelona, Spain
| | - M A Rodriguez-Arias
- Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.,Hospital Universitari Germans Trias i Pujol, Badalona, Spain
| | - J Puig
- Fight AIDS and Infectious Diseases Foundation, Badalona, Spain
| | - I Blanco
- Metropolitana Nord Laboratory, Institut Català de la Salut, Badalona, Spain
| | - C Casañ Lopez
- Microbiology Department, Clinical Laboratory Metropolitana Nord, Badalona, Barcelona, Spain
| | - Á Hernández
- Universitat Autònoma de Barcelona, Barcelona, Spain.,Microbiology Department, Clinical Laboratory Metropolitana Nord, Badalona, Barcelona, Spain
| | - A E Bordoy
- Microbiology Department, Clinical Laboratory Metropolitana Nord, Badalona, Barcelona, Spain
| | - C Esteban Redondo
- Microbiology Department, Clinical Laboratory Metropolitana Nord, Badalona, Barcelona, Spain
| | - V González Soler
- Microbiology Department, Clinical Laboratory Metropolitana Nord, Badalona, Barcelona, Spain.,Centre of Epidemiological Studies of HIV/AIDS and STI of Catalonia (CEEISCAT), Health Department, Generalitat de Catalunya, Badalona, Spain.,CIBER Epidemiologia y Salud Pública (CIBERESP), Madrid, Spain
| | - M Giménez
- Microbiology Department, Clinical Laboratory Metropolitana Nord, Badalona, Barcelona, Spain.,CIBER Enfermedades Respiratorias (CIBERES), Madrid, Spain
| | - V Blanc
- DENTAID Research Center, Cerdanyola del Vallès, Spain
| | - R León
- DENTAID Research Center, Cerdanyola del Vallès, Spain
| | - J Gispert
- DENTAID Research Center, Cerdanyola del Vallès, Spain
| | | | - B Clotet
- Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.,Hospital Universitari Germans Trias i Pujol, Badalona, Spain.,IrsiCaixa AIDS Research Institute, Badalona, Spain.,Universitat de Vic-Universitat Central de Catalunya (UVIC-UCC), Vic, Spain
| | - N Izquierdo-Useros
- IrsiCaixa AIDS Research Institute, Badalona, Spain.,Germans Trias i Pujol Research Institute, Badalona, Spain
| | - O Mitjà
- Fight AIDS and Infectious Diseases Foundation, Badalona, Spain.,Hospital Universitari Germans Trias i Pujol, Badalona, Spain.,Universitat de Vic-Universitat Central de Catalunya (UVIC-UCC), Vic, Spain.,Lihir Medical Centre, International SOS, Lihir Island, Papua New Guinea
| |
Collapse
|
6
|
Páez-Carpio A, Zarco F, Martin C, Vollmer I, García A, Serrano E, Corominas D, Carrero E, Freixa X, Gómez F, Blanco I, Barberà J. Abstract No. 273 Balloon pulmonary angioplasty in patients with non-operable or residual chronic thromboembolic hypertension: initial 5-year experience in a national referral center. J Vasc Interv Radiol 2022. [DOI: 10.1016/j.jvir.2022.03.354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
7
|
Plana‐Pla A, García B, Munera‐Campos M, Catasus N, Serra E, Blanco I, Castellanos E, Bielsa I. Skin Lesions in Neurofibromatosis Type 2: Diagnostic and Prognostic Significance of Cutaneous (Plexiform) Schwannomas. J Eur Acad Dermatol Venereol 2022; 36:1632-1640. [PMID: 35490384 PMCID: PMC9543204 DOI: 10.1111/jdv.18190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2021] [Accepted: 04/07/2022] [Indexed: 12/04/2022]
Abstract
Background Neurofibromatosis type 2 (NF2) is a genetic disease characterized by the appearance of multiple tumours in the nervous system. Cutaneous lesions are common and may provide useful diagnostic and prognostic information, but they have not been widely studied. Objectives To characterize cutaneous lesions in a Spanish cohort of patients with NF2 and investigate associations with clinical and genetic severity. Methods We studied the clinical and histologic characteristics of cutaneous lesions in 49 patients with NF2 and analysed correlations with phenotype‐ and genotype‐based severity scores. We collected information on the presence/absence of cutaneous lesions, location, age at onset, type of lesion, and histologic features. We also studied level of systemic involvement and genetic mutations involved. Results Forty‐nine patients (31 women [63.3%] and 18 men [36.7%]) were analysed, and 33 (67.3%) had cutaneous lesions presumed to be schwannomas. According to their clinical form, they were distributed as follows: 24 patients (48%) had deep tumours, 21 (42%) had plaque‐like lesions, and 3 (6%) had superficial tumours. Histologic examination from 27 lesions analysed out 23 patients showed classic schwannoma or hybrid schwannoma‐neurofibroma features in the 8 deep tumours biopsied and plexiform schwannoma features in the 17 plaque‐like lesions and the 2 superficial tumours analysed. Early onset (first 2 decades of life) was reported by all patients with plaques and superficial tumours. In our cohort, 100% of the patients with plaque‐like lesions and superficial tumours with microscopic features of plexiform schwannoma were in the 2 groups with the most severe clinical phenotypes, and 82.6% of them were in the 3 most severe genotype‐based classes. Conclusions and Relevance Cutaneous lesions, specially plexiform schwannomas, are common in NF2, and they usually appear at an early age providing useful diagnostic and prognostic information. These tumours are part of the spectrum of cutaneous manifestations in this disease. Although its diagnostic and prognostic value has been pointed out, there are few studies focussed on their analysis.
Collapse
Affiliation(s)
- A Plana‐Pla
- Dermatology Department, Hospital Universitari Germans Trias I Pujol (HUGTiP), Badalona. Departament de Medicina, Universitat Autònoma de Barcelona. Badalona Barcelona 08916 Spain
| | - B García
- Clinical Genetics and Genetic Counseling Unit, Clinical Genetics Service, Northern Metropolitan Clinical Laboratory Germans Trias i Pujol University Hospital (HUGTiP) Can Ruti Campus, Badalona Barcelona 08916 Spain
- Hereditary Cancer Group Germans Trias i Pujol Research Institute (IGTP‐PMPPC); Can Ruti Campus Badalona Barcelona 08916 Spain
- Clinical Genomics Unit, Clinical Genetics Service, Northern Metropolitan Clinical Laboratory Germans Trias i Pujol University Hospital (HUGTiP) Can Ruti Campus, Badalona Barcelona 08916 Spain
- Clinical Genomics Research Unit Germans Trias i Pujol Research Institute (IGTP‐PMPPC); Can Ruti Campus Badalona Barcelona 08916 Spain
| | - M Munera‐Campos
- Dermatology Department, Hospital Universitari Germans Trias I Pujol (HUGTiP), Badalona. Departament de Medicina, Universitat Autònoma de Barcelona. Badalona Barcelona 08916 Spain
| | - N Catasus
- Clinical Genomics Research Unit Germans Trias i Pujol Research Institute (IGTP‐PMPPC); Can Ruti Campus Badalona Barcelona 08916 Spain
| | - E Serra
- Hereditary Cancer Group Germans Trias i Pujol Research Institute (IGTP‐PMPPC); Can Ruti Campus Badalona Barcelona 08916 Spain
| | - I Blanco
- Clinical Genetics and Genetic Counseling Unit, Clinical Genetics Service, Northern Metropolitan Clinical Laboratory Germans Trias i Pujol University Hospital (HUGTiP) Can Ruti Campus, Badalona Barcelona 08916 Spain
- Clinical Genomics Research Unit Germans Trias i Pujol Research Institute (IGTP‐PMPPC); Can Ruti Campus Badalona Barcelona 08916 Spain
| | - E Castellanos
- Clinical Genomics Unit, Clinical Genetics Service, Northern Metropolitan Clinical Laboratory Germans Trias i Pujol University Hospital (HUGTiP) Can Ruti Campus, Badalona Barcelona 08916 Spain
- Clinical Genomics Research Unit Germans Trias i Pujol Research Institute (IGTP‐PMPPC); Can Ruti Campus Badalona Barcelona 08916 Spain
| | - I Bielsa
- Dermatology Department, Hospital Universitari Germans Trias I Pujol (HUGTiP), Badalona. Departament de Medicina, Universitat Autònoma de Barcelona. Badalona Barcelona 08916 Spain
| | | |
Collapse
|
8
|
Vallès X, Roure S, Valerio L, López-Muñoz I, Pérez-Quílez O, Soldevila L, Martín-Cano L, Estrada O, Palacín MD, Blanco I, Orozco J, Esquerrà A, Villanova X. SARS-CoV-2 contact tracing among disadvantaged populations during epidemic intervals should be a priority strategy: results from a pilot experiment in Barcelona. Public Health 2021; 195:132-134. [PMID: 34111802 PMCID: PMC8106905 DOI: 10.1016/j.puhe.2021.04.027] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2021] [Accepted: 04/29/2021] [Indexed: 12/13/2022]
Abstract
Objectives The aim of this study was to trace contacts of coronavirus disease 2019 (COVID-19) hospitalised patients and determine the risk factors of infection in urban areas. Study design Longitudinal analysis of contacts identified from index cases. Methods A contact tracing study was carried out in the Northern Metropolitan area of Barcelona, Spain, during the inter-epidemic lapse of May to July 2020, a period of low SARS-CoV-2 incidence. Index cases were notified from the referral hospital. Contacts were traced and followed up for 14 days. Reverse transcription polymerase chain reaction was performed on day 0 and day 14 for contacts. Results In total, 368 contacts were identified from 81 index cases (median of seven contacts per index case), from which 308 were traced successfully. The median age of contacts was 28 years, 62% (223 of 368) were men. During the follow-up period, 100 contacts tested positive for COVID-19 (32.5% [95% confidence interval {CI} = 27.3–38.0]), with a secondary infection rate of 48.3% (95% CI = 40.8–55.9) among housemates. Clusters of index and respective contacts tended to aggregate within disadvantaged neighbourhoods (P < 0.001), and non-national index cases (N = 28, 34.1%) resulted in higher secondary infection rates compared with nationals (51.0% [95% CI = 41.0–60.9] vs 22.3% [95% CI = 16.8–28.8]; P < 0.001). Conclusions Disadvantaged communities experience a disproportionate burden of COVID-19 and may act as infection reservoirs. Contact tracing with a cross-cutting approach among these communities is required, especially during inter-epidemic periods.
Collapse
Affiliation(s)
- X Vallès
- North Metropolitan International Health Program, Primary Care Unit, Universitat Autònoma de Barcelona, Institut Català de la Salut, Passatge dels Encants, s/n, 08914, Badalona, Catalonia, Spain.
| | - S Roure
- North Metropolitan International Health Program, Primary Care Unit, Universitat Autònoma de Barcelona, Institut Català de la Salut, Passatge dels Encants, s/n, 08914, Badalona, Catalonia, Spain; Infectious Diseases Unit, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Institut Català de la Salut, C/ Canyet s/n, 08018, Badalona, Catalonia, Spain
| | - L Valerio
- North Metropolitan International Health Program, Primary Care Unit, Universitat Autònoma de Barcelona, Institut Català de la Salut, Passatge dels Encants, s/n, 08914, Badalona, Catalonia, Spain
| | - I López-Muñoz
- North Metropolitan International Health Program, Primary Care Unit, Universitat Autònoma de Barcelona, Institut Català de la Salut, Passatge dels Encants, s/n, 08914, Badalona, Catalonia, Spain
| | - O Pérez-Quílez
- North Metropolitan International Health Program, Primary Care Unit, Universitat Autònoma de Barcelona, Institut Català de la Salut, Passatge dels Encants, s/n, 08914, Badalona, Catalonia, Spain
| | - L Soldevila
- North Metropolitan International Health Program, Primary Care Unit, Universitat Autònoma de Barcelona, Institut Català de la Salut, Passatge dels Encants, s/n, 08914, Badalona, Catalonia, Spain; Infectious Diseases Unit, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Institut Català de la Salut, C/ Canyet s/n, 08018, Badalona, Catalonia, Spain
| | - L Martín-Cano
- North Metropolitan International Health Program, Primary Care Unit, Universitat Autònoma de Barcelona, Institut Català de la Salut, Passatge dels Encants, s/n, 08914, Badalona, Catalonia, Spain
| | - O Estrada
- Directorate of Innovation, North Metropolitan Health Area from Barcelona, Institut Català de la Salut, C/Canyet s/n, 08018, Badalona, Catalonia, Spain
| | - M D Palacín
- North Metropolitan International Health Program, Primary Care Unit, Universitat Autònoma de Barcelona, Institut Català de la Salut, Passatge dels Encants, s/n, 08914, Badalona, Catalonia, Spain
| | - I Blanco
- Microbiology Unit, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Institut Català de la Salut, C/Canyet s/n, 08018, Badalona, Catalonia, Spain
| | - J Orozco
- Emergency Unit, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Institut Català de la Salut, C/Canyet s/n, 08018, Badalona, Catalonia, Spain
| | - A Esquerrà
- Internal Medicine Unit, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Institut Català de la Salut, C/Canyet s/n, 08018, Badalona, Catalonia, Spain
| | - X Villanova
- North Metropolitan International Health Program, Primary Care Unit, Universitat Autònoma de Barcelona, Institut Català de la Salut, Passatge dels Encants, s/n, 08914, Badalona, Catalonia, Spain
| |
Collapse
|
9
|
Fabijanovic D, Loncaric F, Sarvari S, Vellve K, Rodriguez-Lopez M, Sepulveda-Martinez A, Blanco I, Cikes M, Sitges M, Gratacos E, Bijnens B, Crispi F. Cardiac remodeling in a fetal growth restriction cohort – a follow-up study from preadolescence into adolescence. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3205] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background and aim
The persistence of cardiovascular changes in fetal growth restriction (FGR) has been demonstrated from prenatal to preadolescent age, supporting the hypothesis of primary cardiac programming in FGR and the association between low birth weight and cardiovascular risk in adulthood. The aim was to follow-up the FGR cohort and explore the cardiac function and shape in adolescence.
Methods
FGR was defined by estimated fetal weight and birth weight below the 10th centile, while the control group consisted of normally grown fetuses with birth weight above the 10thcentile. The patients were followed from preadolescence (8–12 years of age) to adolescence (12–17 years of age) with 2-D echocardiography and deformation imaging. The adolescent participants underwent a cardiopulmonary exercise test, where echocardiography was performed at peak exercise. Sphericity index was calculated as the ratio of the LV apex-to-base length and LV basal diameter, measured in 4-chambre view.
Results
The cohort included 56 participants: individuals with FGR (n=22) and controls (n=34). The mean follow-up was 4.4±0.5 years. The preadolescent FGR cohort was younger (10 vs. 11 years, p=0.004), of shorter height, and lower body weight. In FGR, the trend in smaller LV end-diastolic volumes (LVEDV) was paired with a shorter apex-to-base length (63 vs. 68 mm, p=0.006), and a significantly more spherical LV (1.9 vs 2.0, p=0.004). While the LV ejection fraction was preserved, the LV global longitudinal strain (GLS) was reduced (21.21 vs 22.45%, p=0.001) and the relaxation time impaired. In the follow-up adolescent cohort, there were no differences in height, weight, LV dimensions, LV sphericity, LV GLS or relaxation time. During the follow-up period, the FGR cohort had a significantly higher increase in weight (40 vs. 31%, p=0.016) and BMI (18 vs. 11%, p=0.008). The same was seen in cardiac dimensions, showing a higher increase in LVEDV (35 vs. 27%, p=0.049) and the LV base-to-apex length (24 vs. 17%, p<0.001) (Figure 1); but equal increase of the LV basal diameter (p=0.770), resulting in a difference in the change of LV sphericity (0 vs. −13%, p=0.007) between subgroups. The rise in LVGLS was also higher in the FGR cohort (6 vs. 1%, p=0.049). During the exercise test there was no difference in maximal workload (112.5 vs. 125 Watts, p=0.981) or oxygen consumption (28.8 vs. 29.1 mL/min/kg, p=0.076). At peak exercise no differences were seen in cardiac dimensions, LV diastolic or systolic function.
Conclusion
The results suggest changes in cardiac shape and function, described in individuals with FGR in prenatal and preadolescent age, seem to be ameliorated in adolescence related to compensatory growth as compared to healthy controls. These findings offer novel information in the research of elevated cardiovascular risk in adults with FGR.
Figure 1
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- D Fabijanovic
- University Hospital Centre Zagreb, Department of Cardiovascular Diseases, Zagreb, Croatia
| | - F Loncaric
- Institute of Biomedical Research August Pi Sunyer (IDIBAPS), Barcelona, Spain
| | - S Sarvari
- Oslo University Hospital Rikshospitalet, Department of Cardiology, Oslo, Norway
| | - K Vellve
- Hospital Clinic de Barcelona, Hospital Sant Joan de Deu, Fetal Medicine Research Center, BCNatal, Barcelona, Spain
| | - M Rodriguez-Lopez
- Hospital Clinic de Barcelona, Hospital Sant Joan de Deu, Fetal Medicine Research Center, BCNatal, Barcelona, Spain
| | - A Sepulveda-Martinez
- Hospital Clinic de Barcelona, Hospital Sant Joan de Deu, Fetal Medicine Research Center, BCNatal, Barcelona, Spain
| | - I Blanco
- Hospital Clinic de Barcelona, Respiratory Medicine Department, Barcelona, Spain
| | - M Cikes
- University Hospital Centre Zagreb, Department of Cardiovascular Diseases, Zagreb, Croatia
| | - M Sitges
- Hospital Clinic de Barcelona, Institut Clinic Cardiovascular, Barcelona, Spain
| | - E Gratacos
- Hospital Clinic de Barcelona, Hospital Sant Joan de Deu, Fetal Medicine Research Center, BCNatal, Barcelona, Spain
| | - B Bijnens
- Institute of Biomedical Research August Pi Sunyer (IDIBAPS), Barcelona, Spain
| | - F Crispi
- Hospital Clinic de Barcelona, Hospital Sant Joan de Deu, Fetal Medicine Research Center, BCNatal, Barcelona, Spain
| |
Collapse
|
10
|
Simard F, Sanz-De La Garza M, Vaquer-Segui A, Blanco I, Prat-Gonzalez S, Bijnens B, Sitges M. Left atrial performance during exercise in endurance athletes: the impact of gender. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3129] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
High-intensity endurance training is associated with an increased risk of atrial fibrillation (AF) in male athletes while it seems to have a protective effect for the development of atrial arrhythmias in female athletes. Mechanisms underlying this fact are unknown but a differential atrial adaptation to exercise may be involved.
Aim
To evaluate left atrial (LA) performance during exercise in endurance athletes (EAs) of both sexes.
Methods
Highly-trained (>10 hours training/week) EAs performed a maximal cardiopulmonary exercise test. LA evaluation was performed at rest and immediately after exercise. LA analysis consisted of standard and speckle-tracking assessment: atrial contractile, reservoir and conduction strain.
Results
80 EAs (55% women, 34.8±5.8 years) were enrolled. Baseline LA size and functional parameters were similar in both sexes (Table 1). Compared to men, women achieved a higher predicted VO2max (Δchange+11.9%, p<0.01) but a similar increase of systolic blood pressure (Δ+63 vs +66%, p=0.58). Exercise induced a mild decrease in LA size but of similar amplitude for both sexes. LA strain parameters of EAs improved with exercise, but a significantly greater improvement in LA reservoir and conduit function was noted in women compared to men. In EAs with marked atrial remodelling (LA ≥35ml/m2), the same trend of greater improvement of LA reservoir and conduit function in women persisted.
Conclusion
In highly-trained EAs, premenopausal women have better LA function profile during exercise compared to men, even when the LA is significantly dilated. This discriminatory LA adaptation in female EAs could at least partly explain the dichotomous relationship between AF and exercise regarding sexes and warrants further studies to clarify the underlying mechanism.
Funding Acknowledgement
Type of funding source: Public grant(s) – National budget only. Main funding source(s): Government of Spain - Plan Nacional I+D, Ministerio de Economia y Competitividad
Collapse
Affiliation(s)
- F Simard
- Barcelona Hospital Clinic, Cardiovascular Institute, Barcelona, Spain
| | | | - A Vaquer-Segui
- Barcelona Hospital Clinic, Cardiovascular Institute, Barcelona, Spain
| | - I Blanco
- Barcelona Hospital Clinic, Pulmonary Medicine Department, Barcelona, Spain
| | - S Prat-Gonzalez
- Barcelona Hospital Clinic, Cardiovascular Institute, Barcelona, Spain
| | - B Bijnens
- Institute of Biomedical Research August Pi Sunyer (IDIBAPS), Barcelona, Spain
| | - M Sitges
- Barcelona Hospital Clinic, Cardiovascular Institute, Barcelona, Spain
| |
Collapse
|
11
|
Playan Escribano J, Segura De La Cal T, Segovia Cubero J, Rueda Soriano J, Garcia Hernandez F, Lopez Meseguer M, Perez Penate G, Lara Padron A, Campo Ezquibela A, Sala Llinas E, Mombiela T, Guerra Ramos F, Samper G, Blanco I, Escribano Subias P. Pulmonary hypertension and congenital heart disease: medical treatment and risk factors for survival. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.2299] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Pulmonary arterial hypertension (PAH) is a common comorbidity in congenital heart disease (CHD) and significantly affects prognosis. There are four large clinical groups of CHD-related PAH: Eisenmenger syndrome, PAH associated with non-restrictive shunt, PAH associated with restrictive shunt and postoperative PAH. Our purpose was to study the clinical and prognostic differences among them.
Methods
The REHAP is a Spanish multicentre voluntary registry of patients over 14 years of age, which includes patients with CHD and PAH, starting in 2007. 664 patients were analyzed: Baseline characteristics, functional class, right catheterization data, treatment and survival were compared.
Results
664 patients were analyzed: characteristics are detailed in the table. Patients with Eisenmenger were more frequently treated with oral monotherapy as a first line therapy and received less frequently prostanoids during the follow-up. Patients with Eisenmenger had significantly better prognosis, with the best long-term survival of the 4 groups. In a cox regression model, postoperative PAH has a 1.7 hazard ratio (HR) (reference group: Eisenmenger) after adjustment for age (HR 1.02 p 0,001), functional class (HR NYHA III-IV 2.3 p<0,001), sex (p 0.8) and pulmonary vascular resistance (p 0.7).
Conclusion
The clinical classification of PAH associated with CHD defines both the baseline characteristics and the prognosis of patients. Outcome relates closely to functional class and type of PAH–CHD. Eisenmenger group, which has the most severe hemodynamics, is the one with the best prognosis despite a less aggressive treatment.
Funding Acknowledgement
Type of funding source: Private grant(s) and/or Sponsorship. Main funding source(s): Ferrer, Janssen
Collapse
Affiliation(s)
| | | | | | | | | | | | - G.M Perez Penate
- University Hospital Dr Negrin, Las Palmas de Gran Canaria, Spain
| | - A Lara Padron
- University Hospital of the Canaries, Santa Cruz de Tenerife, Spain
| | | | - E Sala Llinas
- University Hospital Son Espases, Palma de Mallorca, Spain
| | - T Mombiela
- University Hospital Gregorio Maranon, Madrid, Spain
| | - F.J Guerra Ramos
- University Hospital Insular of Gran Canaria, Las Palmas De Gran Canaria, Spain
| | - G.J Samper
- General University Hospital of Valencia Consortium, Valencia, Spain
| | - I Blanco
- Hospital Clinic de Barcelona, Barcelona, Spain
| | | |
Collapse
|
12
|
Guillén-del-Castillo A, López-Meseguer M, Tolosa C, Romás Broto A, Colunga Argüelles D, Blanco I, Castro A, López Reyes R, Marín Ballvé A, Otero González I, Fonollosa-Pla V, Sala Llinas E, Escribano Subías P, Simeón-Aznar CP. FRI0242 IMPACT OF PULMONARY ARTERIAL HYPERTENSION WITH OR WITHOUT INTERSTITIAL LUNG DISEASE ON SCLERODERMA: A RETROSPECTIVE COHORT STUDY FROM THE NATIONWIDE SPANISH SCLERODERMA (RESCLE) AND PULMONARY ARTERIAL HYPERTENSION (REHAP) REGISTRIES. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.4302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are the major life-threatening complications in systemic sclerosis (SSc). Data on the impact of PAH and/or ILD in SSc patients (pts) are limited by their low prevalence.Objectives:To assess differences in demographic/clinical characteristics of SSc pts according to presence of PAH and how these are affected by ILD. The impact on characteristics and survival of PAH + ILD was also assessed.Methods:We compared data on SSc pts without PAH from the Spanish registry of patients with SSc (RESCLE) (SSc pts) and SSc pts with PAH from the Spanish registry of pts with PAH (REHAP) (SSc-PAH pts). Only data common in both registries were analyzed. Sub analyses were performed according to the presence/absence of ILD. Transplant-free survival from diagnosis of PAH was estimated using the Kaplan-Meier method.Results:1,579 pts with SSc (RESCLE) and 364 pts with SSc-PAH (REHAP) were analyzed. Compared to SSc pts, SSc-PAH pts had worse functional status (NYHA FC III/IV: 70.6% vs. 8.2% in SSc pts) and pulmonary function (lower mean forced vital capacity [FVC, 81.2±20.6% vs. 93.6±20] and diffusing capacity for carbon monoxide [DLCO, 45.3±17.7% vs. 79.0±36.6%]). More patients had FVC/DLCO ≥1.4 (77.8% vs. 34.8%), tricuspid regurgitation (91.4% vs. 46.1%) or pericardial effusion (30.0% vs. 5.1%). Mean systolic pulmonary artery pressure (sPAP) was higher (70.0±21.3 vs. 27.5±9.1 mmHg) (all respectively; P<0.001 for all). Prevalence of ILD on high-resolution computerized tomography was similar (44.9% [n=92] vs. 41.8% [n=422] in SSc pts; P=0.408). These differences were also found when splitting both cohorts according to the presence / absence of ILD. Compared to SSc-PAH pts without ILD (n=128), pts with PAH + ILD (n=92) had worse functional status (NYHA FC III: 69.6% vs. 55.5% in SSc-PAH pts without ILD; P=0.036), lower mean FVC (70.9±21.9 vs. 86.2±18.6) and lower DLCO (39.4 ±17.0 vs. 49.1±17.9) both P<0.001. Five-year survival rate was 35% in SSc-PAH pts with ILD vs. 45% in SSc-PAH without ILD (P=0.444 [figure 1]).Conclusion:PAH has a profound impact on functional status, pulmonary function and right ventricle function of SSc patients, independently of presence of ILD. Despite the deleterious effect of functional status and pulmonary function, in pts with SSc and PAH, presence of concomitant ILD has no impact on 5-year survival.Disclosure of Interests:Alfredo Guillén-del-Castillo Consultant of: Actelion pharmaceuticals, GSK, MSD., Manuel López-Meseguer Consultant of: Actelion pharmaceuticals, GSK, MSD., Carles Tolosa Consultant of: Actelion pharmaceuticals, GSK, MSD., Antonio Romás Broto Consultant of: Actelion pharmaceuticals, GSK, MSD., Dolores Colunga Argüelles Consultant of: Actelion pharmaceuticals, GSK, MSD., Isabel Blanco Consultant of: Actelion pharmaceuticals, GSK, MSD., Antoni Castro Consultant of: Actelion pharmaceuticals, GSK, MSD., Raquel López Reyes Consultant of: Actelion pharmaceuticals, GSK, MSD., Adela Marín Ballvé: None declared, Isabel Otero González Consultant of: Actelion pharmaceuticals, GSK, MSD., Vicent Fonollosa-Pla Consultant of: Actelion pharmaceuticals, GSK, MSD., Ernest Sala LLinas Consultant of: Actelion pharmaceuticals, GSK, MSD., Pilar Escribano Subías Consultant of: Actelion pharmaceuticals, GSK, MSD., Carmen Pilar Simeón-Aznar Consultant of: Actelion pharmaceuticals, GSK, MSD.
Collapse
|
13
|
Blanco I, Diego I, Bueno P, Fernández E, Casas-Maldonado F, Esquinas C, Soriano JB, Miravitlles M. Geographic distribution of chronic obstructive pulmonary disease prevalence in Africa, Asia and Australasia. Int J Tuberc Lung Dis 2020; 23:1100-1106. [PMID: 31627775 DOI: 10.5588/ijtld.19.0015] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
OBJECTIVE: To visualise spatial data on chronic obstructive pulmonary disease (COPD) prevalence in Africa, Asia and Australasia using a Geographic Information System (GIS) inverse distance weighted (IDW) interpolation technique.DESIGN: Prevalence rates from population surveys on individuals aged ≥40, with spirometry-confirmed COPD, were searched systematically. The prevalence observed in 59 selected surveys and the geographic coordinates of the places where they were conducted informed a GIS computer programme. The prevalence was represented by an ascending chromatic scale (blue-green-yellow-orange-brown-red) in the GIS maps.RESULTS: IDW-interpolation GIS maps were obtained of all the geographic areas investigated, and even from regions lacking data. Areas of high/very high prevalence were found in: Southern Africa and in most of the Central and Eastern Africa regions; in practically all of Central Asia; in the western regions of Southern Asia; in the southern regions of the East European Plain and the West Siberian Plain of Northern Asia; and in the Malay Archipelago. Intermediate prevalence predominated in Oceania and in most of the other regions of Africa and Asia.CONCLUSION: Despite some biases inherent to the interpolation method used in the present study, our approach provided an understandable visual perspective of the COPD prevalence distribution in these geographic regions.
Collapse
Affiliation(s)
- I Blanco
- Alpha1-Antitrypsin Deficiency Spanish Registry (REDAAT), Fundación Respira, Spanish Society of Pneumology and Thoracic Surgery (SEPAR). Barcelona
| | - I Diego
- Materials and Energy Department, School of Mining Engineering, Oviedo University, Oviedo
| | - P Bueno
- Internal Medicine Department, County Hospital of Jarrio, Principality of Asturias
| | - E Fernández
- Clinical Analysis Laboratory, University Hospital of Cabueñes, Gijón
| | | | - C Esquinas
- Pneumology Department, Hospital Universitari Vall d'Hebron/Vall d'Hebron Research Institute (VHIR), Barcelona
| | - J B Soriano
- Instituto de Investigación Hospital Universitario de la Princesa (IISP), Universidad Autónoma de Madrid, Madrid
| | - M Miravitlles
- Pneumology Department, Hospital Universitari Vall d'Hebron/Vall d'Hebron Research Institute (VHIR), Barcelona, CIBER de Enfermedades Respiratorias (CIBERES). Barcelona, Spain
| |
Collapse
|
14
|
Bernardino G, Sanz de la Garza M, Domenech-Ximenos B, Prat-Gonzàlez S, Perea RJ, Blanco I, Burgos F, Sepulveda-Martinez A, Rodriguez-Lopez M, Crispi F, Butakoff C, González Ballester MA, De Craene M, Sitges M, Bijnens B. Three-dimensional regional bi-ventricular shape remodeling is associated with exercise capacity in endurance athletes. Eur J Appl Physiol 2020; 120:1227-1235. [PMID: 32130484 DOI: 10.1007/s00421-020-04335-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2019] [Accepted: 02/25/2020] [Indexed: 12/30/2022]
Abstract
AIMS Endurance athletes develop cardiac remodeling to cope with increased cardiac output during exercise. This remodeling is both anatomical and functional and shows large interindividual variability. In this study, we quantify local geometric ventricular remodeling related to long-standing endurance training and assess its relationship with cardiovascular performance during exercise. METHODS We extracted 3D models of the biventricular shape from end-diastolic cine magnetic resonance images acquired from a cohort of 89 triathlon athletes and 77 healthy sedentary subjects. Additionally, the athletes underwent cardio-pulmonary exercise testing, together with an echocardiographic study at baseline and few minutes after maximal exercise. We used statistical shape analysis to identify regional bi-ventricular shape differences between athletes and non-athletes. RESULTS The ventricular shape was significantly different between athletes and controls (p < 1e-6). The observed regional remodeling in the right heart was mainly a shift of the right ventricle (RV) volume distribution towards the right ventricular infundibulum, increasing the overall right ventricular volume. In the left heart, there was an increment of left ventricular mass and a dilation of the left ventricle. Within athletes, the amount of such remodeling was independently associated to higher peak oxygen pulse (p < 0.001) and weakly with greater post-exercise RV free wall longitudinal strain (p = 0.03). CONCLUSIONS We were able to identify specific bi-ventricular regional remodeling induced by long-lasting endurance training. The amount of remodeling was associated with better cardiopulmonary performance during an exercise test.
Collapse
Affiliation(s)
- G Bernardino
- BCN Medtech, DTIC Universitat Pompeu Fabra, Barcelona, Spain. .,Medisys, Philips, Paris, France.
| | - M Sanz de la Garza
- Cardiovascular Institute, Hospital Clínic, IDIBAPS, Barcelona, Spain.,CIBERCV, Barcelona, Spain
| | - B Domenech-Ximenos
- Cardiovascular Institute, Hospital Clínic, IDIBAPS, Barcelona, Spain.,Radiology Department, Hospital Universitari Dr. Josep Trueta, Girona, Spain
| | - S Prat-Gonzàlez
- Cardiovascular Institute, Hospital Clínic, IDIBAPS, Barcelona, Spain.,CIBERCV, Barcelona, Spain
| | - R J Perea
- Radiology Department, IDIBAPS, Hospital Clinic, Barcelona, Spain
| | - I Blanco
- ICR, IDIBAPS, University of Barcelona, Barcelona, Spain.,Biomedical Research Networking Center on Respiratory Diseases, Madrid, Spain
| | - F Burgos
- ICR, IDIBAPS, University of Barcelona, Barcelona, Spain.,Biomedical Research Networking Center on Respiratory Diseases, Madrid, Spain
| | - A Sepulveda-Martinez
- BCNatal, ICGON, IDIBAPS, Universitat de Barcelona, Barcelona, Spain.,CIBER-ER, Barcelona, Spain.,Fetal Medicine Unit, Department of Obstetrics and Gynecology Hospital Clínico de la Universidad de Chile, Santiago de Chile, Chile
| | - M Rodriguez-Lopez
- BCNatal, ICGON, IDIBAPS, Universitat de Barcelona, Barcelona, Spain.,CIBER-ER, Barcelona, Spain.,Pontificia Universidad Javeriana Cali, Cali, Colombia
| | - F Crispi
- BCNatal, ICGON, IDIBAPS, Universitat de Barcelona, Barcelona, Spain.,CIBER-ER, Barcelona, Spain
| | | | | | | | - M Sitges
- Cardiovascular Institute, Hospital Clínic, IDIBAPS, Barcelona, Spain.,CIBERCV, Barcelona, Spain
| | - B Bijnens
- BCN Medtech, DTIC Universitat Pompeu Fabra, Barcelona, Spain.,ICREA, Barcelona, Spain
| |
Collapse
|
15
|
Wolkenstein P, Guiraud M, Bouroubi A, Beauchamp R, Bocquet A, Grégoire JM, Rauly-Lestienne I, Blanco I, Schmitt AM. Neurofibromes cutanés au cours de la NF1 : opinion d’une communauté de patients sur le fardeau, la prise en charge et les attentes thérapeutiques. Ann Dermatol Venereol 2019. [DOI: 10.1016/j.annder.2019.09.583] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
16
|
Martinez Santos P, Aurtenetxe Perez A, Lopez Gude MJ, Barbera JA, Lopez Meseguer M, Lopez Reyes R, Martinez Menaca A, Lara Padron A, Domingo Morera JA, Blanco I, Escribano Subias P. P4672Current outcome of chronic thromboembolic pulmonary hypertension in Spain. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz745.1054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Chronic thromboembolic pulmonary hypertension (CTEPH) treatment has evolved over the last decade. Increasing evidence regarding new therapeutic developments has shown clinical benefit among these patients in different scenarios. However, there is scarce information about the long-term impact of these achievements in a real-life population on a national scale. We aimed to analyze the impact of current CTEPH therapies on survival in Spain.
Methods
We prospectively collected epidemiological, clinical and prognostic data from CTEPH patients consecutively included in the Spanish REHAP registry from January 1, 2007, to December 31, 2017. All-cause mortality data were gathered during this period.
Results
Eight hundred thirteen patients were included. The mean age was 61 (15) years and 58.1% were women. Out of the 813 patients, 537 (66%) were referred to an expert PH-center. Overall, 245 (30.1%) patients were selected for surgery and 52 (6.4%) for percutaneous treatment and 452 (60.5%) received medical treatment exclusively with specific PH drugs. Survival rates of patients who underwent an invasive procedure (pulmonary thrombendarterectomy or balloon pulmonary angioplasty) were remarkably high.
Figure 1. Cumulative survival from date
Conclusions
Patients who underwent pulmonary thrombendarterectomy or balloon pulmonary angioplasty associated a better outcome.
Acknowledgement/Funding
We gratefully acknowledge all investigators of the REHAP Registry. We express our gratitude to Actelion, Ferrer, GlaxoSmithKline (GSK) and Merck Sharp
Collapse
Affiliation(s)
| | | | | | - J A Barbera
- Hospital Clinic de Barcelona, Barcelona, Spain
| | - M Lopez Meseguer
- Institute of Biomedical Research August Pi Sunyer (IDIBAPS), Barcelona, Spain
| | | | | | - A Lara Padron
- University Hospital of the Canaries, Santa Cruz de Tenerife, Spain
| | | | - I Blanco
- Institute of Biomedical Research August Pi Sunyer (IDIBAPS), Barcelona, Spain
| | | |
Collapse
|
17
|
|
18
|
Bernardino G, Sanz M, Domenech B, Prat S, Sepulveda-Martinez A, Rodriguez-Lopez M, Crispi F, Burgos F, Blanco I, Gonzalez-Ballester MA, Butakoff C, De-Craene M, Sitges M, Bijnens B. 3080Right ventricular morphology remodelling in athletes: an MRI shape analysis study. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.3080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
| | - M Sanz
- Hospital Clinic de Barcelona, Cardiology, Barcelona, Spain
| | - B Domenech
- Hospital Clinic de Barcelona, Cardiology, Barcelona, Spain
| | - S Prat
- Hospital Clinic de Barcelona, Cardiology, Barcelona, Spain
| | - A Sepulveda-Martinez
- Institute of Biomedical Research August Pi Sunyer (IDIBAPS), Fetal i+D Fetal Medicine Research Center, Barcelona, Spain
| | - M Rodriguez-Lopez
- Institute of Biomedical Research August Pi Sunyer (IDIBAPS), Fetal i+D Fetal Medicine Research Center, Barcelona, Spain
| | - F Crispi
- Institute of Biomedical Research August Pi Sunyer (IDIBAPS), Fetal i+D Fetal Medicine Research Center, Barcelona, Spain
| | - F Burgos
- Institute of Biomedical Research August Pi Sunyer (IDIBAPS), Barcelona, Spain
| | - I Blanco
- Institute of Biomedical Research August Pi Sunyer (IDIBAPS), Barcelona, Spain
| | | | - C Butakoff
- University Pompeu Fabra - ICREA, DTIC, Barcelona, Spain
| | | | - M Sitges
- Hospital Clinic de Barcelona, Cardiology, Barcelona, Spain
| | - B Bijnens
- University Pompeu Fabra - ICREA, DTIC, Barcelona, Spain
| |
Collapse
|
19
|
Abstract
This work presents an overview of the text mining area, considering the most common techniques, and including proposals based on the application of fuzzy sets. Besides, some of the most frequent text mining applications are mentioned. We discuss the existing approaches, which we call text data mining, in relation to the recently proposed paradigm of text knowledge mining, and we conclude that both are different and complementary, in the sense that they are able to extract different knowledge pieces from text by using different reasoning mechanisms. Future challenges related to text knowledge mining are also briefly outlined.
Collapse
Affiliation(s)
| | - D. Sánchez
- Department of Computer Science and Artificial Intelligence, University of Granada, Spain
| | - I. Blanco
- Department of Computer Science and Artificial Intelligence, University of Granada, Spain
| | - M. J. Martín-Bautista
- Department of Computer Science and Artificial Intelligence, University of Granada, Spain
| |
Collapse
|
20
|
Aguado L, Fernández-Cahill M, Román FJ, Blanco I, de Echegaray J. Evaluative and Psychophysiological Responses to Short Film Clips of Different Emotional Content. J PSYCHOPHYSIOL 2018. [DOI: 10.1027/0269-8803/a000180] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Abstract. The study presents self-report and psychophysiological data obtained in response to short film clips representing scenes related to different emotions. This was done in order to obtain evidence on the structure of positive and negative affective states following a combined dimensional/categorical approach to emotion and based on responses to stimuli that are more realistic than the static pictures usually employed in the study of emotion. Affective ratings and self-report measures showed a differential structure of the response to positive and negative films (Experiment 1). While all negative films were rated as low in valence and high in arousal, positive films were differentiated into arousing (happy and pleasure contents) and de-arousing (relax contents) categories. A more complex pattern emerged in Experiment 2, using two psychophysiological measures that are differentially sensitive to the main affective dimensions of valence and arousal, skin conductance response (SCR) and facial electromyography (fEMG). First, high arousal positive and negative films produced larger skin conductance responses. Second, fEMG measures showed differentiated response patterns within the positive and negative film categories. Within the positive category, happy and relaxing films had opposed effects, with happy films increasing and relax films decreasing activity over the zygomaticus muscle region. In the case of negative films, only those eliciting disgust produced a differentiated pattern of fEMG activity characterized by large corrugator responses and a modest increase of zygomatic responses. These results are discussed in relation to the adequacy of the dimensional and categorical approaches to emotion, the usefulness of combining subjective and psychophysiological measures, and the advantages of using realistic, dynamic stimuli for the study of emotion.
Collapse
Affiliation(s)
- Luis Aguado
- Facultad de Psicología, Universidad Complutense de Madrid, Spain
| | | | - Francisco J. Román
- Facultad de Psicología, Universidad Autónoma de Madrid, Spain
- Decision Neuscience Laboratory, Beckman Institute for Advanced Science and Technology, University of Illinois at Urbana-Champaign, Urbana, IL, USA
| | - Iván Blanco
- Facultad de Psicología, Universidad Complutense de Madrid, Spain
| | | |
Collapse
|
21
|
Barrado M, Escors D, Arias F, Blanco I, Arteta V, Visus I, Campo M, Flamarique S, Navarrete P, Martínez E. Enzalutamide as a Radiosensitizer in Prostate Cancer Cell Lines. Int J Radiat Oncol Biol Phys 2017. [DOI: 10.1016/j.ijrobp.2017.06.1111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
22
|
Mateo F, Arenas EJ, Aguilar H, Serra-Musach J, de Garibay GR, Boni J, Maicas M, Du S, Iorio F, Herranz-Ors C, Islam A, Prado X, Llorente A, Petit A, Vidal A, Català I, Soler T, Venturas G, Rojo-Sebastian A, Serra H, Cuadras D, Blanco I, Lozano J, Canals F, Sieuwerts AM, de Weerd V, Look MP, Puertas S, García N, Perkins AS, Bonifaci N, Skowron M, Gómez-Baldó L, Hernández V, Martínez-Aranda A, Martínez-Iniesta M, Serrat X, Cerón J, Brunet J, Barretina MP, Gil M, Falo C, Fernández A, Morilla I, Pernas S, Plà MJ, Andreu X, Seguí MA, Ballester R, Castellà E, Nellist M, Morales S, Valls J, Velasco A, Matias-Guiu X, Figueras A, Sánchez-Mut JV, Sánchez-Céspedes M, Cordero A, Gómez-Miragaya J, Palomero L, Gómez A, Gajewski TF, Cohen EEW, Jesiotr M, Bodnar L, Quintela-Fandino M, López-Bigas N, Valdés-Mas R, Puente XS, Viñals F, Casanovas O, Graupera M, Hernández-Losa J, Ramón Y Cajal S, García-Alonso L, Saez-Rodriguez J, Esteller M, Sierra A, Martín-Martín N, Matheu A, Carracedo A, González-Suárez E, Nanjundan M, Cortés J, Lázaro C, Odero MD, Martens JWM, Moreno-Bueno G, Barcellos-Hoff MH, Villanueva A, Gomis RR, Pujana MA. Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. Oncogene 2016; 36:2737-2749. [PMID: 27991928 PMCID: PMC5442428 DOI: 10.1038/onc.2016.427] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2016] [Revised: 08/31/2016] [Accepted: 10/10/2016] [Indexed: 01/16/2023]
Abstract
Inhibitors of the mechanistic target of rapamycin (mTOR) are currently used to treat advanced metastatic breast cancer. However, whether an aggressive phenotype is sustained through adaptation or resistance to mTOR inhibition remains unknown. Here, complementary studies in human tumors, cancer models and cell lines reveal transcriptional reprogramming that supports metastasis in response to mTOR inhibition. This cancer feature is driven by EVI1 and SOX9. EVI1 functionally cooperates with and positively regulates SOX9, and promotes the transcriptional upregulation of key mTOR pathway components (REHB and RAPTOR) and of lung metastasis mediators (FSCN1 and SPARC). The expression of EVI1 and SOX9 is associated with stem cell-like and metastasis signatures, and their depletion impairs the metastatic potential of breast cancer cells. These results establish the mechanistic link between resistance to mTOR inhibition and cancer metastatic potential, thus enhancing our understanding of mTOR targeting failure.
Collapse
Affiliation(s)
- F Mateo
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - E J Arenas
- Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain
| | - H Aguilar
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - J Serra-Musach
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - G Ruiz de Garibay
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - J Boni
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - M Maicas
- Centre for Applied Medical Research (CIMA) and Department of Biochemistry and Genetics, University of Navarra, Pamplona, Spain
| | - S Du
- Department of Radiation Oncology, New York University School of Medicine, New York, NY, USA
| | - F Iorio
- European Molecular Biology Laboratory-European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Cambridge, UK.,Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, UK
| | - C Herranz-Ors
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - A Islam
- Department of Genetic Engineering and Biotechnology, University of Dhaka, Dhaka, Bangladesh
| | - X Prado
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - A Llorente
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - A Petit
- Department of Pathology, University Hospital of Bellvitge, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - A Vidal
- Department of Pathology, University Hospital of Bellvitge, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - I Català
- Department of Pathology, University Hospital of Bellvitge, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - T Soler
- Department of Pathology, University Hospital of Bellvitge, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - G Venturas
- Department of Pathology, University Hospital of Bellvitge, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - A Rojo-Sebastian
- Department of Pathology, MD Anderson Cancer Center, Madrid, Spain
| | - H Serra
- Angiogenesis Research Group, ProCURE, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - D Cuadras
- Statistics Unit, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - I Blanco
- Hereditary Cancer Programme, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - J Lozano
- Department of Molecular Biology and Biochemistry, Málaga University, and Molecular Oncology Laboratory, Mediterranean Institute for the Advance of Biotechnology and Health Research (IBIMA), University Hospital Virgen de la Victoria, Málaga, Spain
| | - F Canals
- ProteoRed-Instituto de Salud Carlos III, Proteomic Laboratory, Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain
| | - A M Sieuwerts
- Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Cancer Genomics Centre, Rotterdam, The Netherlands
| | - V de Weerd
- Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Cancer Genomics Centre, Rotterdam, The Netherlands
| | - M P Look
- Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Cancer Genomics Centre, Rotterdam, The Netherlands
| | - S Puertas
- Chemoresistance and Predictive Factors Laboratory, ProCURE, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - N García
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - A S Perkins
- University of Rochester Medical Center, School of Medicine and Dentistry, Rochester, NY, USA
| | - N Bonifaci
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - M Skowron
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - L Gómez-Baldó
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - V Hernández
- Biological Clues of the Invasive and Metastatic Phenotype Laboratory, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - A Martínez-Aranda
- Biological Clues of the Invasive and Metastatic Phenotype Laboratory, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - M Martínez-Iniesta
- Chemoresistance and Predictive Factors Laboratory, ProCURE, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - X Serrat
- Cancer and Human Molecular Genetics, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
| | - J Cerón
- Cancer and Human Molecular Genetics, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
| | - J Brunet
- Hereditary Cancer Programme, ICO, Girona Biomedical Research Institute (IDIBGI), Girona, Spain
| | - M P Barretina
- Department of Medical Oncology, ICO, IDIBGI, Girona, Spain
| | - M Gil
- Department of Medical Oncology, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - C Falo
- Department of Medical Oncology, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - A Fernández
- Department of Medical Oncology, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - I Morilla
- Department of Medical Oncology, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - S Pernas
- Department of Medical Oncology, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - M J Plà
- Department of Gynecology, University Hospital of Bellvitge, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - X Andreu
- Department of Pathology, Parc Taulí Hospital Consortium, Sabadell, Barcelona, Spain
| | - M A Seguí
- Medical Oncology Service, Parc Taulí Hospital Consortium, Sabadell, Barcelona, Spain
| | - R Ballester
- Department of Radiation Oncology, University Hospital Germans Trias i Pujol, ICO, Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain
| | - E Castellà
- Department of Pathology, University Hospital Germans Trias i Pujol, ICO, IGTP, Badalona, Barcelona, Spain
| | - M Nellist
- Department of Clinical Genetics, Erasmus Medical Centre, Rotterdam, The Netherlands
| | - S Morales
- Hospital Arnau de Vilanova, University of Lleida, Biomedical Research Institute of Lleida (IRB Lleida), Lleida, Spain
| | - J Valls
- Hospital Arnau de Vilanova, University of Lleida, Biomedical Research Institute of Lleida (IRB Lleida), Lleida, Spain
| | - A Velasco
- Hospital Arnau de Vilanova, University of Lleida, Biomedical Research Institute of Lleida (IRB Lleida), Lleida, Spain
| | - X Matias-Guiu
- Hospital Arnau de Vilanova, University of Lleida, Biomedical Research Institute of Lleida (IRB Lleida), Lleida, Spain
| | - A Figueras
- Angiogenesis Research Group, ProCURE, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - J V Sánchez-Mut
- Cancer Epigenetics and Biology Program (PEBC), IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - M Sánchez-Céspedes
- Cancer Epigenetics and Biology Program (PEBC), IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - A Cordero
- Cancer Epigenetics and Biology Program (PEBC), IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - J Gómez-Miragaya
- Cancer Epigenetics and Biology Program (PEBC), IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - L Palomero
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| | - A Gómez
- Cancer Epigenetics and Biology Program (PEBC), IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - T F Gajewski
- Departments of Pathology and Medicine, University of Chicago, Chicago, IL, USA
| | - E E W Cohen
- Moores Cancer Center, University of California San Diego, La Jolla, CA, USA
| | - M Jesiotr
- Department of Pathology, Military Institute of Medicine, Warsaw, Poland
| | - L Bodnar
- Department of Oncology, Military Institute of Medicine, Warsaw, Poland
| | - M Quintela-Fandino
- Breast Cancer Clinical Research Unit, Spanish National Cancer Research Center (CNIO), Madrid, Spain
| | - N López-Bigas
- Department of Experimental and Health Sciences, Barcelona Biomedical Research Park, Pompeu Fabra University (UPF), Barcelona, Spain.,Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
| | - R Valdés-Mas
- Department of Biochemistry and Molecular Biology, University Institute of Oncology of Asturias, University of Oviedo, Oviedo, Spain
| | - X S Puente
- Department of Biochemistry and Molecular Biology, University Institute of Oncology of Asturias, University of Oviedo, Oviedo, Spain
| | - F Viñals
- Angiogenesis Research Group, ProCURE, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - O Casanovas
- Angiogenesis Research Group, ProCURE, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - M Graupera
- Angiogenesis Research Group, ProCURE, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - J Hernández-Losa
- Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain
| | - S Ramón Y Cajal
- Department of Pathology, Vall d'Hebron University Hospital, Barcelona, Spain
| | - L García-Alonso
- European Molecular Biology Laboratory-European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Cambridge, UK
| | - J Saez-Rodriguez
- European Molecular Biology Laboratory-European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Cambridge, UK
| | - M Esteller
- Cancer Epigenetics and Biology Program (PEBC), IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain.,Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.,Department of Physiological Sciences II, School of Medicine, University of Barcelona, Barcelona, Spain
| | - A Sierra
- Molecular and Translational Oncology Laboratory, Biomedical Research Center CELLEX-CRBC, Biomedical Research Institute 'August Pi i Sunyer' (IDIBAPS), and Systems Biology Department, Faculty of Science and Technology, University of Vic, Central University of Catalonia, Barcelona, Spain
| | - N Martín-Martín
- Center for Cooperative Research in Biosciences (CIC bioGUNE), Derio, Spain
| | - A Matheu
- Neuro-Oncology Section, Oncology Department, Biodonostia Research Institute, San Sebastian, Spain.,Ikerbasque, Basque Foundation for Science, Bilbao, Spain
| | - A Carracedo
- Center for Cooperative Research in Biosciences (CIC bioGUNE), Derio, Spain.,Ikerbasque, Basque Foundation for Science, Bilbao, Spain.,Department of Biochemistry and Molecular Biology, University of the Basque Country (UPV/EHU), Bilbao, Spain
| | - E González-Suárez
- Cancer Epigenetics and Biology Program (PEBC), IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - M Nanjundan
- Department of Cell Biology, Microbiology, and Molecular Biology, University of South Florida, Tampa, FL, USA
| | - J Cortés
- Department of Medical Oncology, VHIO, Vall d'Hebron University Hospital, Barcelona, Spain
| | - C Lázaro
- Hereditary Cancer Programme, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - M D Odero
- Centre for Applied Medical Research (CIMA) and Department of Biochemistry and Genetics, University of Navarra, Pamplona, Spain
| | - J W M Martens
- Department of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Cancer Genomics Centre, Rotterdam, The Netherlands
| | - G Moreno-Bueno
- Department of Biochemistry, Autonomous University of Madrid (UAM), Biomedical Research Institute 'Alberto Sols' (Spanish National Research Council (CSIC)-UAM), Translational Research Laboratory, Hospital La Paz Institute for Health Research (IdiPAZ), and MD Anderson International Foundation, Madrid, Spain
| | - M H Barcellos-Hoff
- Department of Radiation Oncology, New York University School of Medicine, New York, NY, USA
| | - A Villanueva
- Chemoresistance and Predictive Factors Laboratory, ProCURE, ICO, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain
| | - R R Gomis
- Oncology Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain.,Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
| | - M A Pujana
- Breast Cancer and Systems Biology Laboratory, Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute of Oncology (ICO), Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain
| |
Collapse
|
23
|
Blanco I, Lipsker D, Lara B, Janciauskiene S. Neutrophilic panniculitis and autoinflammation: what's the link?: reply from authors. Br J Dermatol 2016; 175:647-8. [PMID: 27463611 DOI: 10.1111/bjd.14614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- I Blanco
- Board of Directors of the Alpha1-Antitrypsin Deficiency Spanish Registry, Lung Foundation Breathe, Spanish Society of Pneumology (SEPAR), Barcelona, Spain.
| | - D Lipsker
- Faculté de Medecine, Université de Strasbourg et Clinique Dermatologique, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - B Lara
- Respiratory Medicine Department, Royal Exeter and Devon Hospital, Exeter, U.K
| | - S Janciauskiene
- Department of Respiratory Medicine, Hannover Medical School, Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), Member of the German Center for Lung Research (DZL), Hanover, Germany
| |
Collapse
|
24
|
Jog NR, Blanco I, Lee I, Putterman C, Caricchio R. Urinary high-mobility group box-1 associates specifically with lupus nephritis class V. Lupus 2016; 25:1551-1557. [PMID: 27075010 DOI: 10.1177/0961203316644331] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2015] [Accepted: 03/21/2016] [Indexed: 12/16/2022]
Abstract
INTRODUCTION High-mobility group box 1 protein (HMGB-1) has been implicated in the pathogenesis of lupus nephritis (LN). There is increased HMGB-1 expression in the kidneys and increased levels are observed in serum and urine of patients with LN. This study was performed to determine whether the increased urinary HMGB-1 was specific for active lupus or secondary to renal damage. METHODS Urine from 61 lupus patients (32 had active LN and 29 had systemic lupus erythematosus (SLE) with no evidence of LN) and 14 control proteinuric patients (all with hypertension and eight also with diabetes) were included in this study. HMGB-1 was detected by Western blot. Urine protein was normalized to urine creatinine to account for volume of the specimen. RESULTS Median normalized urine HMGB-1 levels were significantly elevated in LN patients compared to lupus patients without kidney disease (53.81 vs 9.46, p < 0.001). A difference in median levels was seen between LN classes, with a significant difference between proliferative and membranous disease (33.4 vs 138.8, p = 0.003). Urine protein to urine creatinine ratio (P/C) correlated with urinary HMGB-1 (r = 0.52, p < 0.001), but across the classes this was true only for membranous disease (r = 0.71, p = 0.022, proliferative, p = 0.63; mixed, p = 0.34). CONCLUSIONS HMGB-1 is elevated in the urine of patients with active LN. Levels are associated with LN class, and higher levels of urinary HMGB-1 are seen in patients with class V when compared to both proliferative and mixed classes. Therefore, urinary HMGB-1 may be suggestive of membranous LN and warrants further evaluation in a large lupus cohort.
Collapse
Affiliation(s)
- N R Jog
- Rheumatology Section, Department of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA.,Current affiliation: Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA
| | - I Blanco
- Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA
| | - I Lee
- Nephrology Section, Department of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA
| | - C Putterman
- Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA
| | - R Caricchio
- Rheumatology Section, Department of Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA .,Department of Microbiology and Immunology, Lewis Katz School of Medicine at Temple University, Philadelphia, PA, USA
| |
Collapse
|
25
|
Blanco I, Lipsker D, Lara B, Janciauskiene S. Neutrophilic panniculitis associated with alpha-1-antitrypsin deficiency: an update. Br J Dermatol 2016; 174:753-62. [DOI: 10.1111/bjd.14309] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/17/2015] [Indexed: 12/13/2022]
Affiliation(s)
- I. Blanco
- Board of Directors of the Alpha1-Antitrypsin Deficiency Spanish Registry; Lung Foundation Breathe; Spanish Society of Pneumology (SEPAR), Provenza; 108 Bajo 08029 Barcelona Spain
| | - D. Lipsker
- Faculté de Médecine; Université de Strasbourg et Clinique Dermatologique; Hôpitaux Universitaires de Strasbourg; 1 Place de l'Hôpital 67091 Strasbourg CEDEX France
| | - B. Lara
- Respiratory Medicine Department; Royal Exeter and Devon Hospital; Exeter U.K
| | - S. Janciauskiene
- Department of Respiratory Medicine; Hannover Medical School; Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH); Member of the German Center for Lung Research (DZL); 30626 Hanover Germany
| |
Collapse
|
26
|
Ognibene G, Cristaldi DA, Fiorenza R, Blanco I, Cicala G, Scirè S, Fragalà ME. Photoactivity of hierarchically nanostructured ZnO–PES fibre mats for water treatments. RSC Adv 2016. [DOI: 10.1039/c6ra06854e] [Citation(s) in RCA: 34] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Brush-like ZnO nanorods shell grown by CBD onto electrospun PES fibres as photocatalytic membranes for water purification.
Collapse
Affiliation(s)
- G. Ognibene
- Department of Civil Engineering and Architecture
- University of Catania
- 95123 Catania
- Italy
| | - D. A. Cristaldi
- Department of Chemical Science and INSTM UdR Catania
- University of Catania
- I-95123 Catania
- Italy
| | - R. Fiorenza
- Department of Chemical Science and INSTM UdR Catania
- University of Catania
- I-95123 Catania
- Italy
| | - I. Blanco
- Department of Civil Engineering and Architecture
- University of Catania
- 95123 Catania
- Italy
| | - G. Cicala
- Department of Civil Engineering and Architecture
- University of Catania
- 95123 Catania
- Italy
| | - S. Scirè
- Department of Chemical Science and INSTM UdR Catania
- University of Catania
- I-95123 Catania
- Italy
| | - M. E. Fragalà
- Department of Chemical Science and INSTM UdR Catania
- University of Catania
- I-95123 Catania
- Italy
| |
Collapse
|
27
|
Escribano-Subías P, del Pozo R, Román-Broto A, Domingo Morera J, Lara-Padrón A, Elías Hernández T, Molina-Ferragut L, Blanco I, Cortina J, Barberà J. Management and outcomes in chronic thromboembolic pulmonary hypertension: From expert centers to a nationwide perspective. Int J Cardiol 2016; 203:938-44. [DOI: 10.1016/j.ijcard.2015.11.039] [Citation(s) in RCA: 43] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/06/2015] [Revised: 10/19/2015] [Accepted: 11/04/2015] [Indexed: 11/26/2022]
|
28
|
Muñoz-Mediavilla C, Cámara JA, Salazar S, Segui B, Sanguino D, Mulero F, de la Cueva E, Blanco I. Evaluation of the foetal time to death in mice after application of direct and indirect euthanasia methods. Lab Anim 2015; 50:100-7. [PMID: 26265244 DOI: 10.1177/0023677215600626] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Directive 2010/63/EU on the protection of animals used for scientific purposes requires that the killing of mammal foetuses during the last third of their gestational period should be accomplished through effective and humane methods. The fact that murine foetuses are resistant to hypoxia-mediated euthanasia renders the current euthanasia methods ineffective or humane for the foetuses when these methods are applied to pregnant female mice. We have assessed the time to death of foetuses after performing either indirect (dam euthanasia) or direct (via intraplacental injection--a new approach to euthanasia) euthanasia methods in order to determine a euthanasia method that is appropriate, ethical and efficient for the killing of mouse foetuses. The respective times to death of foetuses after performing the three most commonly used euthanasia methods (namely cervical dislocation, CO2inhalation and intraperitoneal sodium pentobarbital administration) were recorded. Absence of foetal heartbeat was monitored via ultrasound. We consider that the most effective and humane method of foetal euthanasia was the one able to achieve foetal death within the shortest possible period of time. Among the indirect euthanasia methods assessed, the administration of a sodium pentobarbital overdose to pregnant female mice was found to be the fastest for foetuses, with an average post-treatment foetal death of approximately 29.8 min. As for the direct euthanasia method assessed, foetal time to death after intraplacental injection of sodium pentobarbital was approximately 14 min. Significant differences among the different mouse strains employed were found. Based on the results obtained in our study, we consider that the administration of a sodium pentobarbital overdose by intraplacental injection to be an effective euthanasia method for murine foetuses.
Collapse
Affiliation(s)
- C Muñoz-Mediavilla
- Charles River Laboratories, Animal Facility Unit, Spanish National Cancer Research Centre - CNIO, Spain
| | - J A Cámara
- Molecular Imaging Unit, Spanish National Cancer Research Centre - CNIO, Spain
| | - S Salazar
- Charles River Laboratories, Animal Facility Unit, Spanish National Cancer Research Centre - CNIO, Spain
| | - B Segui
- Charles River Laboratories, Animal Facility Unit, Spanish National Cancer Research Centre - CNIO, Spain
| | - D Sanguino
- Animal Facility Unit, Spanish National Cancer Research Centre - CNIO, Spain
| | - F Mulero
- Molecular Imaging Unit, Spanish National Cancer Research Centre - CNIO, Spain
| | | | - I Blanco
- Charles River Laboratories, Animal Facility Unit, Spanish National Cancer Research Centre - CNIO, Spain
| |
Collapse
|
29
|
Duque A, López-Gómez I, Blanco I, Vázquez C. Modificación de Sesgos Cognitivos (MSC) en depresión: Una revisión crítica de nuevos procedimientos para el cambio de sesgos cognitivos. Ter Psicol 2015. [DOI: 10.4067/s0718-48082015000200005] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
30
|
Abstract
Alpha-1 antitrypsin (AAT) deficiency is an under-recognized hereditary disorder associated with the premature onset of chronic obstructive pulmonary disease, liver cirrhosis in children and adults, and less frequently, relapsing panniculitis, systemic vasculitis and other inflammatory, autoimmune and neoplastic diseases. Severe AAT deficiency mainly affects Caucasian individuals and has its highest prevalence (1 : 2000-1 : 5000 individuals) in Northern, Western and Central Europe. In the USA and Canada, the prevalence is 1: 5000-10 000. Prevalence is five times lower in Latin American countries and is rare or nonexistent in African and Asian individuals. The key to successful diagnosis is by measuring serum AAT, followed by the determination of the phenotype or genotype if low concentrations are found. Case detection allows implementation of genetic counselling and, in selected cases, the application of augmentation therapy. Over the past decade, it has been demonstrated that AAT is a broad-spectrum anti-inflammatory, immunomodulatory, anti-infective and tissue-repair molecule. These new capacities are promoting an increasing number of clinical studies, new pharmacological formulations, new patent applications and the search for alternative sources of AAT (including transgenic and recombinant AAT) to meet the expected demand for treating a large number of diseases, inside and outside the context of AAT deficiency.
Collapse
Affiliation(s)
- F de Serres
- Center for the Evaluation of Risks to Human Reproduction, National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA
| | | |
Collapse
|
31
|
Estival A, Etxaniz O, Cuadra Urteaga J, Romeo M, Blanco I, Gil M, Ahlal S, Ojanguren I, Indacochea A, Vila L, Balana C. Second Primary Malignances (Spms) in Patients (P) with Gastrointestinal Stromal Tumors (Gists) – a Coincidence or an Effect of Imatinib? Ann Oncol 2014. [DOI: 10.1093/annonc/mdu354.21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
32
|
Cubiella J, Salve M, Díaz-Ondina M, Vega P, Alves MT, Iglesias F, Sánchez E, Macía P, Blanco I, Bujanda L, Fernández-Seara J. Diagnostic accuracy of the faecal immunochemical test for colorectal cancer in symptomatic patients: comparison with NICE and SIGN referral criteria. Colorectal Dis 2014; 16:O273-82. [PMID: 24456168 DOI: 10.1111/codi.12569] [Citation(s) in RCA: 69] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/02/2013] [Accepted: 12/06/2013] [Indexed: 12/15/2022]
Abstract
AIM The diagnostic accuracy of the faecal immunochemical test (FIT) at a 100 ng/ml threshold for colorectal cancer (CRC) was compared with National Institute for Health and Care Excellence (NICE) and the Scottish Intercollegiate Guidelines Network (SIGN) referral criteria. METHOD A multicentre, prospective, blind study of diagnostic tests was carried out in two Spanish health areas. In 787 symptomatic patients referred for a diagnostic colonoscopy, we determined whether patients met NICE and SIGN referral criteria. All patients performed one FIT determination (OCsensor(™) ). The sensitivity and specificity for CRC detection were determined with McNemar's test. The diagnostic odds ratio as well as the number needed to scope (NNS) to detect a CRC were calculated. RESULTS We detected CRC in 97 (12.3%) patients; 241 (30.6%) had an FIT ≥ 100 ng/ml and 300 (38.1%) and 473 (60.1%) met NICE and SIGN referral criteria. The FIT had a higher sensitivity for CRC detection than NICE criteria (87.6%, 61.9%; P < 0.001) and SIGN criteria (82.5%; P = 0.4). The specificity of FIT was also higher than NICE and SIGN criteria (77.4%, 65.2%, 42.7%; P < 0.001). The odds ratios of FIT, NICE and SIGN criteria for the diagnosis of CRC were 24.24 (95% CI 12.91-45.53), 3.04 (95% CI 1.96-4.71) and 3.51 (95% CI 2.03-6.06). The NNS to detect a CRC in individuals with an FIT ≥ 100 ng/ml was 2.83 (95% CI 2.4-3.41) and in individuals who met NICE and SIGN criteria it was 5 (95% CI 3.98-6.37) and 5.95 (95% CI 4.85-7.35). CONCLUSION Our study suggests that FIT is more accurate for the detection of CRC than the current NICE and SIGN referral criteria in symptomatic patients referred for colonoscopy.
Collapse
Affiliation(s)
- J Cubiella
- Department of Gastroenterology, Complexo Hospitalario Universitario de Ourense, Ourense, Spain
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Vargas G, Navarro M, González S, Brunet J, Ramón y Cajal T, Balmaña J, Lázaro C, Blanco I, Pineda M, Capellá G. 996: Prevalence of germline MUTYH mutations among Lynch-like syndrome patients. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)50880-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
34
|
Méndez-Rosado LA, Hechavarría-Estenoz D, de la Torre ME, Pimentel-Benitez H, Hernández-Gil J, Perez B, Barrios-Martínez A, Morales-Rodriguez E, Soriano-Torres M, Garcia M, Suarez-Mayedo U, Cedeño-Aparicio N, Blanco I, Díaz-Véliz P, Vidal-Hernández B, Mitjans-Torres M, Miñoso S, Alvarez-Espinosa D, Reyes-Hernández E, Angulo-Cebada E, Torres-Palacios M, Lozano-Lezcano L, Lima-Rodriguez U, Mayeta M, Noblet M, Benítez Y, Lardoeyt-Ferrer R, Yosela-Martin S, Carbonell P, Pérez-Ramos M, de León N, Perez M, Carbonell J. Current status of prenatal diagnosis in Cuba: causes of low prevalence of Down syndrome. Prenat Diagn 2014; 34:1049-54. [PMID: 24861354 DOI: 10.1002/pd.4421] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2013] [Revised: 05/13/2014] [Accepted: 05/19/2014] [Indexed: 11/05/2022]
Abstract
OBJECTIVES To analyze trends in cytogenetic prenatal diagnosis in Cuba and to analyze possible causes leading to a low Down syndrome prevalence in a country where the triple test is not available. METHODS An analysis of the Cuban program in prenatal cytogenetic diagnosis from 1984 to 2012 was conducted. Results are described, with particular emphasis on indications, abnormal results, types of invasive procedures, and terminations of pregnancy. RESULTS Cytogenetic prenatal diagnostic analyses (n = 75,095) were conducted; maternal age was the indication for 77.9% of the amniocenteses and chorionic villus samplings. The detection rate of chromosomally abnormal pregnancies was 2.3% for maternal age and increased to 8-9% for other indications. When a chromosomal abnormality was identified, 88.5% terminated the pregnancy. In 2002, the live birth prevalence of Down syndrome was 8.4 per 10,000 live births, and in 2012, 7 per 10,000. CONCLUSION Prenatal diagnosis in Cuba has contributed to a significant reduction in chromosomal aberrations. The impact increased because of the demographic trends of the population, the high index of terminations of pregnancy, and the establishment of a network of cytogenetic laboratories throughout Cuba.
Collapse
|
35
|
Broder A, Blanco I, Vila C, Jonhston C, Neugarten J. SAT0009 The Prevalence and Patterns of Antiphospholipid Antibodies in SLE and Non-Sle Patients with END Stage Renal Disease: Table 1. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.4818] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
36
|
Mur P, Pineda M, Romero A, Del Valle J, Borràs E, Canal A, Navarro M, Brunet J, Rueda D, Ramón Y Cajal T, Lázaro C, Caldés T, Blanco I, Soto JL, Capellá G. Identification of a founder EPCAM deletion in Spanish Lynch syndrome families. Clin Genet 2013; 85:260-6. [PMID: 23530899 DOI: 10.1111/cge.12152] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2013] [Revised: 03/22/2013] [Accepted: 03/22/2013] [Indexed: 12/14/2022]
Abstract
Germline deletions at the 3'-end of EPCAM have been involved in the etiology of Lynch syndrome (LS). The aim of this study was to characterize at the molecular level Spanish families harboring EPCAM deletions. Non-commercial multiplex ligation-dependent probe amplification (MLPA) probes and long-range polymerase chain reaction (PCR) amplification were used to characterize each deletion. Haplotyping was performed by analyzing eight microsatellite markers and five MSH2single nucleotide polymorphisms (SNPs). Methylation of MSH2 was analyzed by methylation specific-MLPA. Tumors diagnosed in seven Spanish families harboring EPCAM deletions were almost exclusively colorectal. Mosaicism in MSH2 methylation was observed in EPCAM deletion carrier samples, being average methylation levels higher in normal colon and colorectal tumors (27.6% and 31.1%), than in lymphocytes and oral mucosa (1.1% and 0.7%). Three families shared the deletion c.858 + 2568_*4596del, with a common haplotype comprising 9.9 Mb. In two families the novel EPCAM deletion c.858 + 2488_*7469del was identified. This study provides knowledge on the clinical and molecular characteristics of mosaic MSH2 epimutations. The identification of an EPCAM founder mutation has useful implications for the molecular diagnosis of LS in Spain.
Collapse
Affiliation(s)
- P Mur
- Hereditary Cancer Program, Catalan Institute of Oncology, ICO-IDIBELL, L'Hospitalet de Llobregat, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Clarke AE, Bernatsky S, Costenbader KH, Urowitz MB, Gladman DD, Fortin PR, Petri M, Manzi S, Isenberg DA, Rahman A, Wallace D, Gordon C, Peschken C, Dooley MA, Ginzler EM, Aranow C, Edworthy SM, Nived O, Jacobsen S, Ruiz-Irastorza G, Yelin E, Barr SG, Criswell L, Sturfelt G, Dreyer L, Blanco I, Gottesman L, Feldman CH, Ramsey-Goldman R. Lymphoma risk in systemic lupus: effects of treatment versus disease activity. Arthritis Res Ther 2012. [PMCID: PMC3467493 DOI: 10.1186/ar3950] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
38
|
Cicala G, Blanco I, Latteri A, Oliveri L, Recca A. Influence of 1,5-naphthalenediamine on thermomechanical properties of epoxy/copolyethersulphone blends. POLYM ENG SCI 2012. [DOI: 10.1002/pen.23249] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
39
|
Castillo C, Hernández J, García Vaquero M, López Alonso M, Pereira V, Miranda M, Blanco I, Benedito J. Effect of moderate Cu supplementation on serum metabolites, enzymes and redox state in feedlot calves. Res Vet Sci 2012; 93:269-74. [DOI: 10.1016/j.rvsc.2011.06.014] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2010] [Revised: 05/11/2011] [Accepted: 06/08/2011] [Indexed: 01/05/2023]
|
40
|
Blanco I, Abate L, Antonelli ML, Bottino FA, Bottino P. Phenyl hepta cyclopentyl – polyhedral oligomeric silsesquioxane (ph,hcp-POSS)/Polystyrene (PS) nanocomposites: the influence of substituents in the phenyl group on the thermal stability. EXPRESS POLYM LETT 2012. [DOI: 10.3144/expresspolymlett.2012.105] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
41
|
Blanco I, Díaz D, Moriyón C, Santamaría L, Díez M, López M, Padín H, Cantero F, Artime S, Domínguez F, Aira F, Álvarez-Obregón R. Biopsia de ganglio centinela en pacientes con cáncer de mama y cirugía mamaria previa. ACTA ACUST UNITED AC 2011; 30:223-8. [DOI: 10.1016/j.remn.2011.03.005] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2011] [Revised: 03/03/2011] [Accepted: 03/08/2011] [Indexed: 02/06/2023]
|
42
|
Graña B, Fachal L, Darder E, Balmaña J, Ramón Y Cajal T, Blanco I, Torres A, Lázaro C, Diez O, Alonso C, Santamariña M, Velasco A, Teulé A, Lasa A, Blanco A, Izquierdo A, Borràs J, Gutiérrez-Enríquez S, Vega A, Brunet J. Germline ATM mutational analysis in BRCA1/BRCA2 negative hereditary breast cancer families by MALDI-TOF mass spectrometry. Breast Cancer Res Treat 2011; 128:573-9. [PMID: 21445571 DOI: 10.1007/s10549-011-1462-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2011] [Accepted: 03/15/2011] [Indexed: 12/31/2022]
Abstract
Biallelic inactivation of ATM gene causes the rare autosomal recessive disorder Ataxia-telangiectasia (A-T). Female relatives of A-T patients have a two-fold higher risk of developing breast cancer (BC) compared with the general population. ATM mutation carrier identification is laborious and expensive, therefore, a more rapid and directed strategy for ATM mutation profiling is needed. We designed a case-control study to determine the prevalence of 32 known ATM mutations causing A-T in Spanish population in 323 BRCA1/BRCA2 negative hereditary breast cancer (HBC) cases and 625 matched Spanish controls. For the detection of the 32 ATM mutations we used the matrix-assisted laser desorption/ionization time-of-flight mass spectrometry technique. We identified one patient carrier of the c.8264_8268delATAAG ATM mutation. This mutation was not found in the 625 controls. These results suggest a low frequency of these 32 A-T causing mutations in the HBC cases in our population. Further case-control studies analyzing the entire coding and flanking sequences of the ATM gene are warranted in Spanish BC patients to know its implication in BC predisposition.
Collapse
Affiliation(s)
- B Graña
- High Risk and Cancer Prevention Unit, Vall d'Hebron Institute of Oncology, University Hospital Vall d'Hebron, P. Vall d'Hebron 119-129, 08035 Barcelona, Spain.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Blanco I, Verghese J, Lipton RB, Putterman C, Derby CA. Modifiable predictors of racial differences in gait velocity in an elderly urban cohort. Ann Rheum Dis 2011. [DOI: 10.1136/ard.2011.151209.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
44
|
Theodoratou E, Campbell H, Tenesa A, Houlston R, Webb E, Lubbe S, Broderick P, Gallinger S, Croitoru EM, Jenkins MA, Win AK, Cleary SP, Koessler T, Pharoah PD, Küry S, Bézieau S, Buecher B, Ellis NA, Peterlongo P, Offit K, Aaltonen LA, Enholm S, Lindblom A, Zhou XL, Tomlinson IP, Moreno V, Blanco I, Capellà G, Barnetson R, Porteous ME, Dunlop MG, Farrington SM. A large-scale meta-analysis to refine colorectal cancer risk estimates associated with MUTYH variants. Br J Cancer 2010; 103:1875-84. [PMID: 21063410 PMCID: PMC3008602 DOI: 10.1038/sj.bjc.6605966] [Citation(s) in RCA: 95] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Background: Defective DNA repair has a causal role in hereditary colorectal cancer (CRC). Defects in the base excision repair gene MUTYH are responsible for MUTYH-associated polyposis and CRC predisposition as an autosomal recessive trait. Numerous reports have suggested MUTYH mono-allelic variants to be low penetrance risk alleles. We report a large collaborative meta-analysis to assess and refine CRC risk estimates associated with bi-allelic and mono-allelic MUTYH variants and investigate age and sex influence on risk. Methods: MUTYH genotype data were included from 20 565 cases and 15 524 controls. Three logistic regression models were tested: a crude model; adjusted for age and sex; adjusted for age, sex and study. Results: All three models produced very similar results. MUTYH bi-allelic carriers demonstrated a 28-fold increase in risk (95% confidence interval (CI): 6.95–115). Significant bi-allelic effects were also observed for G396D and Y179C/G396D compound heterozygotes and a marginal mono-allelic effect for variant Y179C (odds ratio (OR)=1.34; 95% CI: 1.00–1.80). A pooled meta-analysis of all published and unpublished datasets submitted showed bi-allelic effects for MUTYH, G396D and Y179C (OR=10.8, 95% CI: 5.02–23.2; OR=6.47, 95% CI: 2.33–18.0; OR=3.35, 95% CI: 1.14–9.89) and marginal mono-allelic effect for variants MUTYH (OR=1.16, 95% CI: 1.00–1.34) and Y179C alone (OR=1.34, 95% CI: 1.01–1.77). Conclusions: Overall, this large study refines estimates of disease risk associated with mono-allelic and bi-allelic MUTYH carriers.
Collapse
Affiliation(s)
- E Theodoratou
- Colon Cancer Genetics Group and Academic Coloproctology, MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Rivera B, González S, Sánchez-Tomé E, Blanco I, Mercadillo F, Letón R, Benítez J, Robledo M, Capellá G, Urioste M. Clinical and genetic characterization of classical forms of familial adenomatous polyposis: a Spanish population study. Ann Oncol 2010; 22:903-909. [PMID: 20924072 DOI: 10.1093/annonc/mdq465] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Classical familial adenomatous polyposis (FAP) is characterized by the appearance of >100 colorectal adenomas. PATIENTS AND METHODS We screened the APC and MUTYH genes for mutations and evaluated the genotype-phenotype correlation in 136 Spanish classical FAP families. RESULTS APC/MUTYH mutations were detected in 107 families. Sixty-four distinct APC point mutations were detected in 95 families of which all were truncating mutations. A significant proportion (39.6%) had not been previously reported. Mutations were spread over the entire coding region and great rearrangements were identified in six families. Another six families exhibited biallelic MUTYH mutations. No APC or MUTYH mutations were detected in 29 families. These APC/MUTYH-negative families showed clinical differences with the APC-positive families. A poor correlation between phenotype and mutation site was observed. CONCLUSIONS Our results highlight that a broad approach in the genetic study must be considered for classical FAP due to involvement of both APC and MUTYH and the heterogeneous spectrum of APC mutations observed in this Spanish population. The scarcely consistent genotype-phenotype correlation does not allow making specific recommendations regarding screening and management. Differences observed in APC/MUTYH-negative families may reflect a genetic basis other than mutations in APC and MUTYH genes for FAP predisposition.
Collapse
Affiliation(s)
- B Rivera
- Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Valencia; Human Genetics Group, Human Cancer genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid
| | - S González
- Molecular Diagnosis Unit, Hereditary Cancer Program, IDIBELL-Catalan Institute of Oncology, Barcelona
| | - E Sánchez-Tomé
- Human Genetics Group, Human Cancer genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid
| | - I Blanco
- Genetic Counseling Unit, Hereditary Cancer Program, IDIBELL and FIGTP-Catalan Institute of Oncology, Barcelona
| | - F Mercadillo
- Human Genetics Group, Human Cancer genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid
| | - R Letón
- Hereditary Endocrine Cancer Group, Human Cancer Genetics Programme, CNIO, Madrid
| | - J Benítez
- Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Valencia; Human Genetics Group, Human Cancer genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid
| | - M Robledo
- Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Valencia; Hereditary Endocrine Cancer Group, Human Cancer Genetics Programme, CNIO, Madrid
| | - G Capellá
- Hereditary Cancer Program, IDIBELL-Catalan Institute of Oncology, Barcelona, Spain
| | - M Urioste
- Centro de Investigaciones Biomédicas en Red de Enfermedades Raras (CIBERER), Valencia; Human Genetics Group, Human Cancer genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid.
| |
Collapse
|
46
|
Mitra AV, Bancroft EK, Barbachano Y, Page EC, Foster CS, Jameson C, Mitchell G, Lindeman GJ, Stapleton A, Suthers G, Evans DG, Cruger D, Blanco I, Mercer C, Kirk J, Maehle L, Hodgson S, Walker L, Izatt L, Douglas F, Tucker K, Dorkins H, Clowes V, Male A, Donaldson A, Brewer C, Doherty R, Bulman B, Osther PJ, Salinas M, Eccles D, Axcrona K, Jobson I, Newcombe B, Cybulski C, Rubinstein WS, Buys S, Townshend S, Friedman E, Domchek S, Ramon Y Cajal T, Spigelman A, Teo SH, Nicolai N, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Eyfjord J, Falconer A, Grönberg H, Hamdy F, Johannsson O, Khoo V, Kote-Jarai Z, Lilja H, Lubinski J, Melia J, Moynihan C, Peock S, Rennert G, Schröder F, Sibley P, Suri M, Wilson P, Bignon YJ, Strom S, Tischkowitz M, Liljegren A, Ilencikova D, Abele A, Kyriacou K, van Asperen C, Kiemeney L, Easton DF, Eeles RA. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int 2010; 107:28-39. [PMID: 20840664 DOI: 10.1111/j.1464-410x.2010.09648.x] [Citation(s) in RCA: 79] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
OBJECTIVE To evaluate the role of targeted prostate cancer screening in men with BRCA1 or BRCA2 mutations, an international study, IMPACT (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls), was established. This is the first multicentre screening study targeted at men with a known genetic predisposition to prostate cancer. A preliminary analysis of the data is reported. PATIENTS AND METHODS Men aged 40-69 years from families with BRCA1 or BRCA2 mutations were offered annual prostate specific antigen (PSA) testing, and those with PSA > 3 ng/mL, were offered a prostate biopsy. Controls were men age-matched (± 5 years) who were negative for the familial mutation. RESULTS In total, 300 men were recruited (205 mutation carriers; 89 BRCA1, 116 BRCA2 and 95 controls) over 33 months. At the baseline screen (year 1), 7.0% (21/300) underwent a prostate biopsy. Prostate cancer was diagnosed in ten individuals, a prevalence of 3.3%. The positive predictive value of PSA screening in this cohort was 47·6% (10/21). One prostate cancer was diagnosed at year 2. Of the 11 prostate cancers diagnosed, nine were in mutation carriers, two in controls, and eight were clinically significant. CONCLUSIONS The present study shows that the positive predictive value of PSA screening in BRCA mutation carriers is high and that screening detects clinically significant prostate cancer. These results support the rationale for continued screening in such men.
Collapse
Affiliation(s)
- Anita V Mitra
- The Institute of Cancer Research, Sutton, Surrey, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Beggs AD, Latchford AR, Vasen HFA, Moslein G, Alonso A, Aretz S, Bertario L, Blanco I, Bülow S, Burn J, Capella G, Colas C, Friedl W, Møller P, Hes FJ, Järvinen H, Mecklin JP, Nagengast FM, Parc Y, Phillips RKS, Hyer W, Ponz de Leon M, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Tejpar S, Thomas HJW, Wijnen JT, Clark SK, Hodgson SV. Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut 2010; 59:975-86. [PMID: 20581245 DOI: 10.1136/gut.2009.198499] [Citation(s) in RCA: 414] [Impact Index Per Article: 29.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Peutz-Jeghers syndrome (PJS, MIM175200) is an autosomal dominant condition defined by the development of characteristic polyps throughout the gastrointestinal tract and mucocutaneous pigmentation. The majority of patients that meet the clinical diagnostic criteria have a causative mutation in the STK11 gene, which is located at 19p13.3. The cancer risks in this condition are substantial, particularly for breast and gastrointestinal cancer, although ascertainment and publication bias may have led to overestimates in some publications. Current surveillance protocols are controversial and not evidence-based, due to the relative rarity of the condition. Initially, endoscopies are more likely to be done to detect polyps that may be a risk for future intussusception or obstruction rather than cancers, but surveillance for the various cancers for which these patients are susceptible is an important part of their later management. This review assesses the current literature on the clinical features and management of the condition, genotype-phenotype studies, and suggested guidelines for surveillance and management of individuals with PJS. The proposed guidelines contained in this article have been produced as a consensus statement on behalf of a group of European experts who met in Mallorca in 2007 and who have produced guidelines on the clinical management of Lynch syndrome and familial adenomatous polyposis.
Collapse
Affiliation(s)
- A D Beggs
- Department of Clinical Genetics, St Georges, University of London, Cranmer Terrace, London, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Menéndez M, Castellví-Bel S, Pineda M, De Cid R, Muñoz J, González S, Teulé À, Balaguer F, Ramón y Cajal T, Reñé JM, Blanco I, Castells A, Capellà G. Founder effect of a pathogenic MSH2 mutation identified in Spanish families with Lynch syndrome. Clin Genet 2010; 78:186-90. [DOI: 10.1111/j.1399-0004.2009.01346.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
|
49
|
de Serres FJ, Blanco I, Fernández-Bustillo E. Estimates of PI*S and PI*Z Alpha-1 antitrypsin deficiency alleles prevalence in the Caribbean and North, Central and South America. Monaldi Arch Chest Dis 2010; 71:96-105. [PMID: 19999955 DOI: 10.4081/monaldi.2009.354] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND AAT deficiency is not a rare disease, but one of the most common congenital disorders increasing susceptibility of individuals with this deficiency to both lung and liver disease as well as other several adverse health effects. Studies to develop accurate estimates of the magnitude of this genetic disorder in any given country is critical for the development of screening programs for detection, diagnosis, and treatment of those individuals and/or families at risk. In the present study, estimates of the prevalence of the two major deficiency alleles PI S and PI Z were estimated for 25 countries in the Caribbean and North, Central, and South America to supplement our previous studies on 69 countries worldwide. METHOD Using data on the prevalence of the two most common deficiency alleles PI S and PIZ in the mother countries that provided the majority of immigrants to these 25 countries, as well as genetic epidemiological studies on various genetic subgroups indigenous to the Caribbean and North, Central and South America it was possible to develop new formulas to estimate the numbers in each of five phenotypic classes, namely PI MS, PI MZ, PI SS, PI SZ and PI ZZ for each country. RESULTS When these 25 countries were grouped into six different geographic regions, the present study demonstrated striking differences when comparisons were made in numeric tables, maps and figures. Highly significant numbers of individuals at risk for AAT Deficiency were found in both the European, Mestizo and Mulatto populations for most of the 25 countries studied in the Caribbean and North, Central and South America. CONCLUSIONS Our studies demonstrated striking differences in the prevalence of both the PIS and PIZ alleles among these 25 countries in the Caribbean and North, Central and South America and significant numbers of individuals at risk for adverse health effects associated with AAT Deficiency in a given country. When these data are added to the results from our earlier studies on 69 countries, we now have data on AAT Deficiency in 94 of the 193 countries worldwide listed in the CIA FactBook.
Collapse
Affiliation(s)
- F J de Serres
- Center for the Evaluation of Risks to Human Reproduction, Environmental Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709-2233, USA
| | | | | |
Collapse
|
50
|
Navarro M, Binefa G, Blanco I, Guardiola J, Rodríguez-Moranta F, Peris M. Colorectal cancer screening: strategies to select populations with moderate risk for disease. Rev esp enferm dig 2009; 101:855-60. [DOI: 10.4321/s1130-01082009001200005] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|